A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Table 3

Proportion of patients achieving target HbA1c < 7% in each treatment arm.

	Metformin Arm 1 (N = 51)		Low-dose NW Low-Glu®Arm 2 (N = 54)		High-dose NW Low-Glu® Arm 3 (N = 52)
Count (%)	95% CI	Count (%)	95% CI	Count (%)	95% CI
HbA1c < 7%	21 (41.2)	27.2–55.2	19 (35.2)	22.0–48.3	14 (26.9)	14.5–39.4
HbA1c ≥ 7%	30 (58.8)	44.8–72.8	35 (64.8)	51.7–77.9	38 (73.1)	60.6–85.6

Chi-square test used to compare between three arms revealed . Note. Percentages were calculated from patients with available HbA1c measurements at week 12.